Dr. rer. nat. Björn Moosmann
Rechtsmedizin · Dept. IV
Novel Receptor-Binding-Based Assay for the Detection of Opioids in Human Urine Samples.
Bergerhoff M, Moosmann B. Novel Receptor-Binding-Based Assay for the Detection of Opioids in Human Urine Samples. Anal Chem 2023
27.01.2023Novel Receptor-Binding-Based Assay for the Detection of Opioids in Human Urine Samples.
27.01.2023Anal Chem 2023
Bergerhoff Maja, Moosmann Björn
Development of a non-radioactive mass spectrometry-based binding assay at the μ-opioid receptor and its application for the determination of the binding affinities of 17 opiates/opioids as well as of the designer opioid isotonitazene and five further 2-benzylbenzimidazoles
Volz M, Moosmann B. Development of a non-radioactive mass spectrometry-based binding assay at the μ-opioid receptor and its application for the determination of the binding affinities of 17 opiates/opioids as well as of the designer opioid isotonitazene and five further 2-benzylbenzimidazoles. Anal Chim Acta 2022; 1219:339978.
23.05.2022Development of a non-radioactive mass spectrometry-based binding assay at the μ-opioid receptor and its application for the determination of the binding affinities of 17 opiates/opioids as well as of the designer opioid isotonitazene and five further 2-benzylbenzimidazoles
23.05.2022Anal Chim Acta 2022; 1219:339978
Volz Madeleine Ramona, Moosmann Björn
Cross reactivity of the CEDIA and HEIA benzodiazepine kits for 29 designer benzodiazepines and tofisopam
Erdmann J, Moosmann B. Cross reactivity of the CEDIA and HEIA benzodiazepine kits for 29 designer benzodiazepines and tofisopam. Drug Test Anal 2021; 13:1686-1688.
24.06.2021Cross reactivity of the CEDIA and HEIA benzodiazepine kits for 29 designer benzodiazepines and tofisopam
24.06.2021Drug Test Anal 2021; 13:1686-1688
Erdmann Joana, Moosmann Björn
New psychoactive substances—Designer benzodiazepines
Moosmann B. New psychoactive substances—Designer benzodiazepines. WIREs Forensic Science 2021; 3:1416-1439.
28.03.2021New psychoactive substances—Designer benzodiazepines
28.03.2021WIREs Forensic Science 2021; 3:1416-1439
Moosmann Björn
Verzögerter Todeseintritt nach Einnahme von Natrium-Pentobarbital
Kissling S, Blum S, Beyer J, Moosmann B, Hausmann R (2020). Verzögerter Todeseintritt nach Einnahme von Natrium-Pentobarbital. Präsentiert bei: DGRM Jahrestagung, Luzern
05.09.2020Verzögerter Todeseintritt nach Einnahme von Natrium-Pentobarbital
05.09.2020DGRM Jahrestagung
Kissling Steffen, Blum Simon, Beyer Jochen, Moosmann Björn, Hausmann Roland
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). Drug Test Anal 2019; 11:541-549.
05.02.2019Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
05.02.2019Drug Test Anal 2019; 11:541-549
Moosmann Björn, Bisel Philippe, Westphal Folker, Wilde Maurice, Kempf Jürgen, Angerer Verena, Auwärter Volker
5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA
Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V. 5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicol 2018; 37:186-196.
13.11.20185F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA
13.11.2018Forensic Toxicol 2018; 37:186-196
Angerer Verena, Franz Florian, Moosmann Björn, Bisel Philippe, Auwärter Volker
Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples
Mogler L, Franz F, Wilde M, Huppertz L, Halter S, Angerer V, Moosmann B, Auwärter V. Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples. Drug Test Anal 2018; 10:1417-1429.
23.05.2018Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples
23.05.2018Drug Test Anal 2018; 10:1417-1429
Mogler Lukas, Franz Florian, Wilde Maurice, Huppertz Laura M, Halter Sebastian, Angerer Verena, Moosmann Björn, Auwärter Volker
Designer Benzodiazepines: Another Class of New Psychoactive Substances
Moosmann B, Auwärter V. Designer Benzodiazepines: Another Class of New Psychoactive Substances. In: New Psychoactive Substances. Springer, Cham, 2018. S. 383-410.
01.01.2018Designer Benzodiazepines: Another Class of New Psychoactive Substances
01.01.2018Springer, Cham
Moosmann Björn, Auwärter Volker
Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples
Mogler L, Moosmann B, Kassiou M, Banister S, Longworth M, Weinfurtner G, Angerer V, Rentsch D, Franz F, Auwärter V. Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. Drug Test Anal 2017; 10:196-205.
24.05.2017Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples
24.05.2017Drug Test Anal 2017; 10:196-205
Mogler Lukas, Moosmann Björn, Kassiou Michael, Banister Samuel D, Longworth Mitchell, Weinfurtner Georg, Angerer Verena, Rentsch Daniel, Franz Florian, Auwärter Volker
Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine
Huppertz L, Moosmann B, Auwärter V. Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal 2017; 10:206-211.
19.05.2017Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine
19.05.2017Drug Test Anal 2017; 10:206-211
Huppertz Laura M, Moosmann Björn, Auwärter Volker
Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten
Moosmann B. Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten. In: Handbuch Psychoaktive Substanzen. Heidelberg: Springer, 2016. S. 389-409.
01.01.2017Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten
01.01.2017Springer
Moosmann Björn